Latest News and Press Releases

Junshi Biosciences' toripalimab (LOQTORZI®) was approved as the first and only approved immuno-oncology treatment for NPC in Singapore.

– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients...

–  LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or...

- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments - - Many...

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report –...

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...

NEWARK, Del, May 04, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Nasopharyngeal carcinoma treatment market is expected to grow at a value of 5.9% CAGR, according to Future...

SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....

New York, United States , March 30, 2023 (GLOBE NEWSWIRE) -- The Global Nasopharyngeal Carcinoma Market Size is projected to reach multimillion USD by 2030, in comparison to 2021, at a CAGR of 5.6%...

- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - - BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - -...